Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 8/20 | 0.57 |
| ▸ | NPY4R | P50391 | 8/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.57 |
| ▸ | NPY1R | P25929 | 6/20 | 0.57 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.53 |
| ▸ | TFPI | P10646 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363034 | 0.98 | BACE1 (0.60) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL29835097 | 0.98 | CALCR (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30362874 | 0.98 | CALCR (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL29501059 | 0.97 | BACE1 (0.59) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30363072 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL29626845 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30761771 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30362923 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30362943 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R | |
| SCHEMBL30363122 | 0.97 | BACE1 (0.58) | CALCRBACE1NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124889-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | VOYAGER THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-116162128-A | Nucleoside derivative for resisting virus infection and preparation method and application thereof | 知和(山东)大药厂有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230075314-A1 | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF | VOYAGER THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220395544-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | VOYAGER THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11299751-B2 | Compositions for the treatment of disease | VOYAGER THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3966227-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | Voyager Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3963055-A1 | VECTORIZED ANTIBODIES (VAB) AND USES THEREOF | Voyager Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |